GlassScriptPhysician profile
Nick H Shannon
NPI 1619076114
$5,701.25
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,378 · 2020: $1,235 · 2021: $1,121 · 2022: $923 · 2023: $853 · 2024: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.75 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $820.86 | 2019-2021 | |
| Amgen INC. | $720.27 | 2019-2024 | Otezla, Repatha |
| Novo Nordisk INC | $523.49 | 2019-2024 | |
| Lilly USA, LLC | $489.07 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Mannkind Corporation | $340.20 | 2022-2023 | Afrezza |
| Glaxosmithkline, LLC. | $334.98 | 2020-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $313.80 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $266.23 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Amarin Pharma, INC. | $235.89 | 2020-2021 | |
| Esperion Therapeutics, INC. | $225.15 | 2020-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $189.24 | 2019-2022 | |
| Radius Health, INC. | $156.17 | 2019-2021 | |
| Abbott Laboratories | $118.38 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $114.30 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $100.75 | 2021-2024 | Austedo Xr |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.37 | 2019-2023 | |
| Abbvie INC. | $90.61 | 2019-2023 | Vraylar |
| Althera Pharmaceuticals LLC | $74.93 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $70.57 | 2020-2022 | |
| Exact Sciences Corporation | $69.86 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $60.86 | 2022-2023 | |
| Stryker Corporation | $57.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.30 | 2019-2021 | |
| Boston Scientific Corporation | $33.33 | 2019 | |
| Astellas Pharma US INC | $29.56 | 2021 | |
| Dexcom, INC. | $26.55 | 2024 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $24.38 | 2020 | |
| Bioventus LLC | $20.27 | 2019 | |
| Genentech USA, INC. | $18.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.74 | 2020 | |
| Jazz Pharmaceuticals INC. | $16.77 | 2021 | |
| Allergan, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Shannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.